Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With <i>BRAF</i> V600E-Mutated Gliomas

Abstract

Combination of BRAF/MEK inhibition can be a novel, promising approach as targeted therapy in gliomas with <i>BRAF</i> V600 E mutations, especially those that are resistant to standard therapy. Our cases, along with other early reports utilizing dabrafenib/trametinib, highlight the importance of somatic next-generation sequencing, particularly in younger patients. Interim results from clinical trials utilizing dabrafenib/trametinib have been promising thus far, and our case series suggests that durable clinical benefit is possible, even in the setting of glioblastoma, WHO grade IV.